Biodexa Pharmaceuticals Faces Nasdaq Delisting
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company dedicated to creating innovative treatments for diseases that lack effective solutions. Recently, the company announced that it has received a notification from Nasdaq regarding its status on the stock exchange.
Details of the Delisting Determination
On August 27, 2024, Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) received a Staff Determination letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC. This letter stated that the company’s securities would be delisted from The Nasdaq Capital Market. The delisting was prompted by the company’s securities closing below $1.00 for 30 consecutive business days, which is in violation of Nasdaq Listing Rule 5550(a)(2).
Compliance Period and Hearing Request
Typically, companies are allowed a 180-calendar day period to comply with listing rules. However, Biodexa is not eligible for this compliance window because it has executed reverse stock splits in the past two years with a cumulative ratio exceeding 250 to 1. As a result, the company must take swift action.
Plans to Appeal the Decision
Biodexa plans to request a hearing before the Nasdaq Hearings Panel. This request will temporarily halt any suspension or delisting actions while the hearing and any potential extensions are reviewed. The company is determined to tackle this issue and improve its standing in the market.
About Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC, which trades on NASDAQ under the ticker symbol BDRX, is focused on developing advanced treatments for various diseases. Its innovative product pipeline features several promising programs, including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive brain cancer.
Innovative Product Development
eRapa is a unique oral formulation of rapamycin (sirolimus) that functions as an mTOR inhibitor. This product aims to target critical signaling pathways involved in cellular metabolism and growth, especially during tumor progression.
Seeking Diabetes Solutions with Tolimidone
Tolimidone is designed to be a potent and selective inhibitor of Lyn kinase, primarily impacting hematopoietic cells. This formulation has shown promise in animal studies for achieving glycemic control, potentially offering a groundbreaking approach to blood glucose regulation.
Technological Advancements
MTX110 provides a novel solution through a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This innovative delivery method enables the drug to be administered directly at the tumor site, effectively bypassing the blood-brain barrier and minimizing the risk of systemic toxicity—an important advantage in the treatment of aggressive brain tumors.
Company Support and Research Focus
Biodexa utilizes three proprietary drug delivery technologies designed to enhance the bioavailability and distribution of medications within the body. The company operates its headquarters and research facilities in Cardiff, UK, where it concentrates on advancing its drug development initiatives.
Frequently Asked Questions
What is the reason for Biodexa's delisting from Nasdaq?
Biodexa's securities were determined to be delisted because they maintained a closing bid price below $1.00 for 30 consecutive days, triggering Nasdaq Listing Rule 5550(a)(2).
What is the next step for Biodexa regarding the delisting?
The company intends to file a request for a hearing which will suspend any immediate delisting actions during the proceedings.
What are Biodexa's main products under development?
Biodexa is developing several key products, including eRapa for specific cancers, tolimidone for type 1 diabetes, and MTX110 targeting aggressive brain cancers.
How does eRapa work?
eRapa is an oral formulation of rapamycin, an mTOR inhibitor that plays a significant role in regulating cellular growth and metabolism, particularly in cancer cells.
Where is Biodexa Pharmaceuticals based?
The company is headquartered in Cardiff, UK, where it also conducts its research and development activities.
